What the research found

Researchers tracking aging bone marrow in mice identified a chain reaction that undermines bone health with age. They found that immune cells called macrophages progressively activate a signaling pathway called STING as mice age. This activation appears triggered by a combination of factors: inflammatory signals from aging fat cells in the marrow, bacterial endotoxins that accumulate with age, and internal mitochondrial damage within the macrophages themselves.

When activated macrophages accumulate in aging marrow, they impair the ability of stem cells to develop into bone-building osteoblasts. The research team discovered that STING activation in macrophages increases production of an enzyme called CD38, which degrades NAD⁺—both inside the macrophages and in the extracellular space. This depletion of NAD⁺ appears to compromise the energy metabolism of bone-forming cells, reducing their capacity to build new bone tissue.

By silencing the STING gene specifically in macrophages between 12 and 18 months of age, researchers preserved bone density and structure in aging mice. A combination intervention—blocking STING pharmacologically while supplementing with NMN (a NAD⁺ precursor)—produced similar protective effects on bone density, bone formation markers, and cellular energy production in bone-forming cells.

Why it matters for you

If you're tracking bone markers or concerned about osteoporosis risk, this work suggests a testable mechanism linking systemic inflammation, NAD⁺ depletion, and bone loss. The pathway they've mapped—involving macrophage activation, CD38 activity, and NAD⁺ availability—aligns with why some users report improved bone outcomes when combining anti-inflammatory protocols (controlling endotoxin, managing metabolic endotoxemia) with NAD⁺ support. This gives mechanistic grounding to those approaches.

The interplay between mitochondrial health and bone preservation is particularly relevant if you monitor ATP production, lactate clearance, or oxygen utilization as proxy markers of cellular energy. The research suggests that improving macrophage mitochondrial function—via reducing inflammatory triggers or supporting NAD⁺ metabolism—may indirectly benefit osteoblast energy status and bone turnover. This could influence how you prioritize interventions: managing gut barrier integrity and endotoxin load might be upstream of supplementation strategies.

The finding that NMN alone showed only partial rescue in aged conditions suggests that NAD⁺ precursor supplementation works better alongside other interventions that reduce the inflammatory drivers of NAD⁺ depletion. This implies careful protocol layering—combining NMN or NR with STING pathway modulation or upstream inflammation control—may be more effective than isolated NAD⁺ boosting for bone health in aging.

Caveats

• Animal model only: All work was conducted in mice; translation to human bone biology and efficacy of these interventions in people is unproven.
• Pharmacological STING inhibitor not yet clinically available: H-151 is a research tool; no human safety or efficacy data exist.
• Mechanism inferred from correlation: While the chain of events is plausible and supported by targeted experiments, the exact contribution of each factor (DPP4, LPS, mitochondrial DNA) to human bone loss remains unclear.
• Long-term safety unknown: Six months of STING inhibition in mice has not been assessed for off-target effects in bone or immune function in humans.
• DPP4 effect modest in isolation: DPP4 alone did not robustly trigger STING; it required an inflammatory context, complicating predictive value for individual interventions.